Intellia Therapeutics (NTLA) Other Accumulated Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Other Accumulated Expenses data on file, last reported at $11.8 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 289.49% year-over-year to $11.8 million in Q1 2026; TTM through Mar 2026 was $11.8 million, a 289.49% increase from a year earlier, with the FY2025 full-year figure at $17.4 million, down 34.12% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $11.8 million, down from $17.4 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for NTLA reached as high as $30.3 million in Q3 2022 and fell as low as $2.3 million in Q3 2024.
• Historically, Other Accumulated Expenses has averaged $12.9 million across 5 years, with a median of $5.7 million in 2023.
• Across the five-year window, Other Accumulated Expenses soared 1179.88% in 2022 and tumbled 90.5% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $5.0 million in 2022, then surged by 452.98% to $27.4 million in 2023, then decreased by 3.83% to $26.4 million in 2024, then plunged by 34.12% to $17.4 million in 2025, then slumped by 32.11% to $11.8 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $11.8 million in Q1 2026, $17.4 million in Q4 2025, and $5.6 million in Q3 2025.